THE BOTTOM LINE
- Higher Import Costs: Importers of high-dose vitamin and mineral products face significant import duties (e.g., 12.8% in this case) unless the products are explicitly marketed for treating specific medical conditions. The 0% tariff for “medicaments” will not apply.
- Marketing Determines Classification: For customs purposes, the product’s packaging, label, and leaflet are decisive. General health claims like “supports the immune system” are insufficient; the product must specify the diseases or ailments it is intended to treat or prevent to be classified as a medicine.
- Stricter Legal Standard Confirmed: This ruling clarifies that a specific EU Customs rule (Additional Note 1 to Chapter 30 of the Combined Nomenclature) sets a strict, two-part test for these products, prioritizing on-pack information over the product’s high potency alone.
THE DETAILS
In a significant decision for importers and manufacturers of nutritional products, the Amsterdam Court of Appeal has overturned a lower court’s ruling, concluding that a high-dose Vitamin C product must be classified as a food supplement, not a medicine, for customs tariff purposes. The case involved an importer who argued that their Vitamin C tablets, containing over 12 times the recommended daily allowance, possessed therapeutic and prophylactic qualities, thereby qualifying them for a 0% import tariff under the “medicament” category (customs post 3004). Customs authorities disagreed, levying a 12.8% tariff by classifying the product as a “food preparation” (post 2106). The Amsterdam Court of Appeal ultimately sided with Customs, providing crucial clarity on this fine line.
The court’s decision hinged on a specific piece of EU customs law: Additional Note 1 to Chapter 30 of the Combined Nomenclature. This rule establishes a clear, two-part test for vitamin-based preparations to be considered medicines. The first condition—that the product contains a dose “significantly higher” than the recommended daily amount for maintaining general health—was met. However, the product failed the second, equally critical condition: it was not presented as a medicine. The court found that for a product to be classified as a medicament, its label, packaging, or accompanying leaflet must explicitly state (a) the specific diseases, ailments, or symptoms it is used for, (b) the concentration of active ingredients, (c) the dosage, and (d) the method of administration.
This ruling underscores a vital principle for businesses: for customs classification, presentation can be more important than potential. The importer’s product was labelled a “food supplement,” and its marketing materials cited general benefits like “supporting the immune system” and “reducing fatigue.” These claims, the court found, are characteristic of a food supplement, not a product designed to treat a specific medical condition. The court also dismissed the idea that a product’s therapeutic nature could be determined by referring to external sources like scientific literature or previous court decisions. The classification must be based on the objective characteristics of the product as it is presented to customs authorities at the time of import. This strict interpretation sets a clear, predictable standard for the industry.
SOURCE
Source: Gerechtshof Amsterdam
